Overview

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Status:
Terminated
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Japan Breast Cancer Research Network
Treatments:
Anastrozole
Aromatase Inhibitors
Citric Acid
Estrogen Antagonists
Estrogen Receptor Modulators
Toremifene